Department of PharmacoTherapy, PharmacoEpidemiology & PharmacoEconomics, University of Groningen, Groningen Research Institute of Pharmacy, Groningen, the Netherlands; General Practitioners Research Institute, Groningen, the Netherlands.
Department of Clinical Pharmacology and Aged Care, Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, Australia.
J Am Med Dir Assoc. 2020 Aug;21(8):1086-1092.e1. doi: 10.1016/j.jamda.2020.05.037.
Anticholinergic/antimuscarinic and sedative medications (eg, benzodiazepines) have been found to be associated with poorer cognitive and physical function and mobility impairment in older age. However, previous studies were mostly conducted among community-dwelling older individuals and had often a cross-sectional design. Accordingly, our aim was to examine longitudinal associations between cumulative exposure to anticholinergic and sedative medications and cognitive and physical function among residents from aged care homes.
Longitudinal study.
A total of 4624 residents of Dutch aged care homes of whom data were collected between June 2005 and April 2014.
Outcome measures were collected with the Long-Term Care Facilities assessment from the international Residential Assessment Instrument (interRAI-LTCF) and included the Cognitive Performance Scale, the Activities of Daily Living (ADL) Hierarchy scale, a timed 4-meter walk test, distance walked, hours of physical activity, and days being outside. Cumulative exposure to anticholinergic and sedative medications was calculated with the Drug Burden Index (DBI), a linear additive pharmacological dose-response model. Associations were examined with linear mixed models to take the potential dependence of observations into account (ie, data were collected at repeated assessment occasions of residents who were clustered in aged care homes). Analyses were adjusted for sex, age, dementia, comorbidity (neurological, psychiatric, cardiovascular, oncological, and pulmonary), fractures, depressive symptoms, and medications excluded from the DBI.
We observed significant longitudinal associations between a higher DBI and poorer ADLs, fewer hours of physical activity, and fewer days being outside. We found no significant longitudinal association between a higher DBI and poorer cognitive function.
Over time, cumulative exposure to anticholinergic and sedative medications is associated with poorer physical but not cognitive function in aged care residents. Careful monitoring of aged care residents with high cumulative anticholinergic and sedative medication exposure is needed.
已发现抗胆碱能/抗毒蕈碱和镇静药物(如苯二氮䓬类)与老年人认知和身体功能以及行动障碍较差有关。然而,先前的研究主要是在社区居住的老年人中进行的,而且往往是横断面设计。因此,我们的目的是研究长期护理院居民中累积抗胆碱能和镇静药物暴露与认知和身体功能之间的纵向关联。
纵向研究。
共有 4624 名荷兰长期护理院居民的数据收集时间为 2005 年 6 月至 2014 年 4 月。
使用国际长期护理评估工具(interRAI-LTCF)中的长期护理设施评估收集结果测量值,包括认知表现量表、日常生活活动(ADL)等级量表、4 米定时步行测试、行走距离、体力活动时间和户外活动天数。累积抗胆碱能和镇静药物暴露量用药物负担指数(DBI)计算,这是一种线性加性药理剂量反应模型。使用线性混合模型检查关联,以考虑观察结果的潜在依赖性(即,数据是在居民重复评估时收集的,这些居民聚类在长期护理院)。分析调整了性别、年龄、痴呆、合并症(神经、精神、心血管、肿瘤和肺部)、骨折、抑郁症状和排除在 DBI 之外的药物。
我们观察到较高的 DBI 与较差的 ADL、较少的体力活动时间和较少的户外活动天数之间存在显著的纵向关联。我们没有发现较高的 DBI 与较差的认知功能之间存在显著的纵向关联。
随着时间的推移,累积抗胆碱能和镇静药物暴露与长期护理院居民的身体功能下降有关,但与认知功能下降无关。需要仔细监测累积抗胆碱能和镇静药物暴露量较高的长期护理院居民。